About AnGes
About AnGes
Top Message
Values
Mission
Business Area
Business Model
Company Profile
Board of Directors
Locations
History
Alliance Status
Pipeline
Pipeline
Main pipeline products
Product for HGF gene therapy
NF-κB Decoy Oligo DNA
Vaccine
Global Alliance
Global Alliance
EmendoBio, Inc.
MyBiotics Pharma Ltd.
Barcode Diagnostics.
Investor Relations
Investor Relations
IR News
Stock Performance
Financial Reports
Intellectual Property Reports
Other Information Materials
Analyst Report
IR STREET(IR related information)
IR STREET(Email Alerts)
Corporate Brochure
Contact us
COVID-19
Contact us
Site Policy
Privacy Policy
JP
EN
Leading Global in Gene Medicine
About AnGes
TOPIC
Our COVID-19 Related Project
News
All
Development
Product Info
IR
Information
2021.08.06
IR
Consolidated Financial Report for the Second Quarter 2021
2021.05.13
IR
Revised Consolidated Financial Report for the First Quarter 2021
2021.05.10
IR
Consolidated Financial Report for the First Quarter 2021
2021.04.12
IR
AnGes’ Phase 1b Trial Demonstrates Safety and Preliminary, Sustained Efficacy 12 Months After a Single Injection of NF-kappa B Oligo DNA Decoy in Subjects with Chronic Discogenic Low Back Pain
2021.03.25
IR
COVID-19 Treatment AV-001: Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy
Learn more
Pipeline
Learn more
Global Alliance
Learn more
Contact us
